Research programme: botulinum toxin vaccine - Emergent BioSolutionsAlternative Names: Bivalent botulinum vaccine; rBOT
Latest Information Update: 12 Sep 2014
At a glance
- Originator Emergent BioSolutions; Health Protection Agency Porton Down
- Developer Emergent BioSolutions
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Botulism
Most Recent Events
- 12 Sep 2014 No development reported - Preclinical for Botulism in USA and United Kingdom (Parenteral)